Atherosclerotic Cardiovascular Disease Clinical Trials in Birmingham, Alabama
3 recruitingBirmingham, Alabama
Showing 1–3 of 3 trials
Recruiting
Phase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled95 locationsNCT06813911
Recruiting
Phase 3
Pelacarsen Roll-over Extension Program
Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals599 enrolled97 locationsNCT06875973
Recruiting
Not Applicable
Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure
HypertensionAtherosclerotic Cardiovascular Disease
University of Alabama at Birmingham300 enrolled1 locationNCT06962488